ChemoCentryx, Inc.
TREATMENT OF C3 GLOMERULOPATHY USING A C5A INHIBITOR
Last updated:
Abstract:
Methods of treating certain human patient populations suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.
Status:
Application
Type:
Utility
Filling date:
20 Dec 2021
Issue date:
18 Aug 2022